INTRODUCTION

Lung cancer is the number one killer among cancers in the United States with an estimated 154,050 deaths reported in 2018. It is also the second most diagnosed cancer in the United States and is responsible for more than 200,000 new cases per year. Lung cancers can be broadly classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) with NSCLCs accounting for about 85%-90% of lung cancer cases. Clinically, the majority of lung cancer patients do not respond well to current chemo-/radio-therapeutic regimens and have a dismal 5-year survival rate of less than 15%. Recently, the introduction of targeted therapy and immunotherapy has given new hope to NSCLC patients, but the outcome/prognosis is still far from satisfactory. Immunotherapy more recently has become the most revolutionary treatment for solid tumours patients. Among NSCLC patients with PD-L1 expression...
in more than 50% of tumour cells, treatment with Pembrolizumab, which targets PD-1, leads to a superior progression-free and overall survival compared to platinum-doublet chemotherapy in the first-line setting. Furthermore, the addition of Pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significant longer progression-free survival and overall survival irrespective to PD-L1 expression. However, the resistance to immunotherapy and hyper-progressive disease of checkpoint inhibitors treatment has been recently reported in some NSCLC patients. Thus, there is still an urgent need to better understand the mechanisms of lung carcinogenesis and to develop novel therapies (alone or combination of existing treatments) for lung cancer patients.

Dysregulation of mRNA translation is a frequent feature of neoplasia. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. Over the last two decades, the eukaryotic initiation factor 4F (EIF4F) complex has been shown to play important roles in oncogenesis. As an important component of the EIF4F complex, EIF4G1 protein serves as a scaffold and interacts with several other initiation factors such as EIF4E and EIF4A and helps to initiate cap-dependent translation in mammalian cells by recruiting ribosomes to the capped end of mRNA. In contrast to extensive studies of EIF4E and EIF4A components, much less attention has been paid to the function of EIF4G1. For example, several recent studies have indicated that EIF4E protein levels are associated with NSCLC cell proliferation, migration, invasion, epithelial-to-mesenchymal transition (EMT) and chemo-resistance. Although EIF4G1 is overexpressed in a variety of cancers, its role in NSCLC pathogenesis especially immunoregulatory functions, clinical relevance and therapeutic potential remains largely unknown. One study showed that 4EGI-1, one of EIF4G1 inhibitors, enhanced the apoptotic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) on NSCLC cell lines, through inducing CCAAT/enhancer binding protein homologous protein-dependent DR5 and ubiquitin/proteasome-mediated degradation of cellular FLICE-inhibitory protein (c-FLIP). However, the investigators do not focus on the cellular functions of EIF4G1 including its controlled downstream proteins, and the efficacy of EIF4G1 targeted therapy in vivo remains unclear.

Our recently published data demonstrate for the first time that stable silencing of EIF4G1 by shRNA causes significant reduction of proliferation and anchorage-independent growth in NSCLC cell lines (e.g. A549, H460, H1299). Furthermore, EIF4G1 was potentially required for NSCLC metastasis through promoting tumour cell migration and invasion. In the current study, we explore the clinical implications of EIF4G1 by using NSCLC tissue microarrays and other clinical databases, determine the efficacy of selective EIF4G1 inhibitors in NSCLC xenograft models and identify new EIF4G1-controlled cellular proteins in NSCLC cells as well as validating their functions.

2 | MATERIALS AND METHODS

2.1 | Cell culture and reagents

NSCLC cell lines (A549, H460, H1299) were kindly provided by Dr Hua Lu at Tulane University (purchased from ATCC, Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% foetal bovine serum and 1% penicillin and streptomycin. All experiments were performed with mycoplasma-free cells. 4EGI-1 and 4E1RCat were purchased from SelleckChem (Houston, TX, USA). NSCLC formalin-fixed, paraffin-embedded (FFPE) tissue arrays were purchased from US Biomax (Derwood, MD, USA), containing normal lung tissues (n = 10), tumour and paired adjacent tissues from the same patients (n = 45), including 19 cases of LUAD (lung adenocarcinomas) and 26 cases of LUSC (lung squamous cell carcinomas). Protein arrays and analyses were performed in RayBiotech, Inc (Guangzhou, China) by using RayBio Human Protein Array G (Glass–chip-based protein arrays containing 499 targets).

2.2 | Immunohistochemistry

Immunohistochemistry was performed with the Avidin-Biotin-Peroxidase complex, according to the manufacturer’s instructions (Vector Laboratories). Our modified protocol includes paraaffin melting at 58°C in a regular oven for 20 minutes, deparaffinization in xyylene, re-hydration through descending grades of alcohol up to water, and non-enzymatic antigen retrieval in 0.01 M sodium citrate buffer, pH 6.0, heated to 95°C for 40 minutes in a vacuum oven. After a cooling period of 30 minutes, the slides were rinsed in PBS and treated with 3% H2O2 in methanol for 25 minutes to quench endogenous peroxidase. Sections were then blocked with 5% normal horse serum (for mouse monoclonal antibodies), or normal goat serum (for rabbit polyclonal antibodies) in 0.1% PBS/BSA for 2 hours at room temperature. Primary antibodies were incubated overnight at room temperature in a humidifier chamber. Primary antibodies utilized in the present study included rabbit polyclonal anti-EIF4G1 (Abcam, Cambridge, MA, USA, Cat. #ab2609, 1:100 dilution) and anti-NRG1 (Abcam, Cat. #ab53104, 1:500 dilution), mouse monoclonal anti-PD-1 (Abcam, Cat. #ab52587, 1:100 dilution) and a rabbit monoclonal anti-PD-L1 (Abcam, Cat. #ab205921, 1:500 dilution). In the second day, slides were thoroughly rinsed with PBS, and biotinylated secondary anti-mouse or anti-rabbit antibodies were incubated for 1 hour at room temperature (1:200 dilution). Then, sections were incubated with avidin-biotin-peroxidase complexes (Vectastain ABC Elite kit; Vector Laboratories) for 1 hour at room temperature, rinsed with PBS and developed with diaminobenzidine (DAB tablets, Sigma, St. Louis, MO, USA) for three minutes. Finally, the sections were counterstained with Haematoxylin and mounted with Permount (Fisher Scientific, Waltham, MA, USA).
were performed as described previously. Images were collected by Haematoxylin & Eosin (H&E) and immunohistochemistry (IHC) for Ki67 of the tumours were excised for subsequent histopathological analysis.

The mice were observed and measured every 3 days for the size of palpable tumours for additional 3 weeks. At the end of experiment, the mice were killed and tumours were excised and compared. All the animal protocols were approved (# 3380) by the LSUHSC Animal Care and Use Committees in accordance with national guidelines.

2.7 | Statistical analysis
The protein expression of EIF4G1, PD-1, PD-L1, MUC1 and NRG1 in tumour tissues was measured as an ordinal variable with the four strength levels: negative (-), weak (+), intermediate (+++) and strong (+++/+++++). The pairwise correlations of proteins in NSCLC tumour tissues were tested using the Spearman correlations. The correlations of protein expression levels in NSCLC tumour tissues were evaluated using the Pearson correlations. Differences of protein expression levels between experimental and control groups were tested using the two-sided t test, and P values < .05 were considered significant. The 50% Inhibitory Concentrations (IC50) were calculated by using SPSS v20.0.

3 | RESULTS

3.1 | Clinical implications of EIF4G1 in NSCLC patients
NSCLC tissue arrays, which contain normal lung tissues (n = 10), tumour and paired adjacent tissues from the same patients (n = 45), were used to measure EIF4G1 expression through immunohistochemistry. The results indicated that in almost all of patients (LUAD and LUSC), EIF4G1 expression was significantly more robust in tumour tissues than paired adjacent or normal lung tissues (Figure 1A-C), although its expressional levels showed some variation among different patients’ tumour tissues based on IHC scores: − (2/45), ++ (9/45), +++ (12/45), ++++ (22/45). The information about clinical characters and IHC scores for each patient involved in tissue arrays were listed in Supplemental Table 1. However, no significant correlation was found between EIF4G1 expression and tumour TNM, grade or stage (data not shown), which is probably because of the limited number of cases analysed here. By using NSCLC clinical data from The Cancer Genome Atlas (TCGA) cohort, we found that the mRNA level of EIF4G1 were closely related to NSCLC patients’ overall survival through Kaplan-Meier survival analyses, particularly in LUAD patients (Figure 1D). Taken together, these data strongly support the important clinical relevance of EIF4G1 in NSCLC progression and pathogenesis.

3.2 | Regulation of immune checkpoint molecules by EIF4G1 in NSCLC patients
Recent studies have revealed that the EIF4F complex may have immunoregulatory functions (especially regulation of key immune
checkpoint molecules) in the tumour microenvironment. For example, programmed cell death 1 (PD-1) can bind to EIF4E and promote its phosphorylation in hepatocellular carcinoma cells. We recently have developed a RNA-Sequencing-based pipeline to analyse the correlation of key regulatory factors and common immune checkpoint molecules in tumour microenvironment. Gene expression was determined by RSEM pipeline using GRCH38 reference genome. The Pearson correlations were calculated based on the gene TPM values and visualized as the heat maps using R packages. After analysis of RNA-Sequencing data sets of 20 LUAD and 20 LUSC samples from TCGA cohort, the results showed that EIF4G1 potentially up-regulated inhibitory checkpoint molecules whereas down-regulating stimulatory checkpoint molecules in tumour microenvironment. Gene expression was determined by RSEM pipeline using GRCH38 reference genome. The Pearson correlations were calculated based on the gene TPM values and visualized as the heat maps using R packages. After analysis of RNA-Sequencing data sets of 20 LUAD and 20 LUSC samples from TCGA cohort, the results showed that EIF4G1 potentially up-regulated inhibitory checkpoint molecules whereas down-regulating stimulatory checkpoint molecules (Figure 2A-B), which may facilitate tumour cell immune escape for both subtypes of NSCLC. To further confirm these analyses, the same NSCLC tissue arrays above were used to detect the expressional levels of PD-1 and PD-L1, two of major immune checkpoint molecules. The results indicated that both PD-1 and PD-L1 expressions were significantly higher in tumour tissues than paired adjacent or normal lung tissues (Figure 2C-F). Moreover, most of NSCLC cases with positive for EIF4G1 expression (+ + + + + + + +) were also positive for PD-1 (53.3%, 24/45) and/or PD-L1 (91.1%, 41/45). However, silencing of EIF4G1 by RNAi was not able to down-regulate PD-L1 expression from NSCLC cell lines (Figure S1), indicating that EIF4G1 does not directly control PD-L1 translation.

### 3.3 EIF4G1 selective inhibitors effectively repress NSCLC cell growth

Currently, there are a limited number of EIF4G1 specific inhibitors commercially available. 4EGI-1 and 4E1RCat are two small-molecule competitive inhibitors that can prevent EIF4G:EIF4E interaction as well as EIF4F complex formation. Our results indicated that both 4EGI-1 and 4E1RCat treatments effectively reduced the growth of NSCLC cell lines, including H460, A549, H1299, in a dose-dependent manner (IC50 at ~ 8.0-11.0 μM), whereas they displayed almost no inhibitory effects on normal human bronchial epithelial cells (NHBE) at the same range of concentrations (IC50 > 100 μM) (Figure 3A-B). This is probably because of the obvious elevation of EIF4G1 expression in NSCLC cell lines compared to normal lung cells as described previously.
Table 1. Most of these downstream proteins have never been reported to be regulated by EIF4G1, whereas they showed a close protein-protein interaction network and potential functional association (Figure 4A). Interestingly, the Gene Ontology (GO) enrichment analysis indicated that many of EIF4G1-controlled proteins were involved in immune cell migration, chemotaxis, regulation of inflammatory responses, including cytokines and chemokines activities (Figure 4B-C). KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis indicated that the NF-κB signalling pathway activity was potentially affected by EIF4G1 (Figure S2A). The immunoblot results confirmed that knockdown of EIF4G1 by RNAi significantly reduced the phosphorylation of NF-κB p65 kinase from all the 3 NSCLC cell lines being tested (Fig. S2B). Notably, some recent studies have reported the regulation of immune checkpoint molecules by NF-κB signalling pathway in different types of cancer.22-24 Taken together, these data indicate again the potential immunoregulatory function of EIF4G1 network in NSCLC tumour cells.

TABLE 1. The top 10 proteins significantly up-regulated and/or down-regulated in NSCLC H1299 EIF4G1 stably knockdown cell line identified from protein array analyses.

| Gene symbol | Protein description | Fold change |
|-------------|---------------------|-------------|
| ALB         | Albumin             | 29.1        |
| AGT         | Angiotensinogen     | 26.9        |
| NTF3        | Neurotrophin 3      | 19.7        |
| TGFB3       | Transforming growth factor, beta 3 | 9.7 |
| CA242       | Cancer Antigen 242  | 8.5         |
| ANGPT4      | Angiopoietin 4      | 7.0         |
| NTN1        | Netrin 1            | 6.3         |
| NOV         | Nephroblastoma overexpressed | 4.4 |
| CA27-29     | Cancer Antigen 27-29| 3.4         |
| CCL19       | Chemokine (C-C motif) ligand 19 | 3.4 |
| CCR5        | Chemokine (C-C motif) receptor 5 (gene/pseudogene) | 0.2 |
| CCL14       | Chemokine (C-C motif) ligand 14 | 0.15        |
| GAPDH       | Glyceraldehyde-3-phosphate dehydrogenase | 0.14        |
| SDC1        | Syndecan 1          | 0.13        |
| MUC1        | Mucin 1, cell surface associated | 0.09        |
| PPY         | Pancreatic polypeptide | 0.06       |
| PGF         | Placental growth factor | 0.06 |
| PGLYRP1     | Peptidoglycan recognition protein 1 | 0.04 |
| CXCL3       | Chemokine (C-X-C motif) ligand 3 | 0.04 |
| NRG1        | Neuregulin 1        | 0.03        |

As the principal function of EIF4G1 is to control cellular gene translation, a protein array was used for the identification of the signature EIF4G1-controlled proteins in NSCLC cells. The results identified 24 proteins significantly up-regulated and 54 proteins significantly down-regulated (≥ twofold & P < .05) from EIF4G1 stably knockdown H1299 cell line when compared to the parental cell line. The top 10 significantly up-regulated or down-regulated proteins were listed in Table 1. An established NSCLC xenograft model,21 the results indicated that both 4EGI-1 and 4E1RCat treatments significantly repressed H460 tumour growth in vivo (Figure 3C-D). H&E and Ki67 labelling revealed that both 4EGI-1 and 4E1RCat treatments significantly repressed NSCLC tumour growth in vivo (Figure 3E-F).

3.4 | Identification of the signature of EIF4G1-controlled proteins in NSCLC cells

As the principal function of EIF4G1 is to control cellular gene translation, a protein array was used for the identification of the signature EIF4G1-controlled proteins in NSCLC cells. The results identified 24 proteins significantly up-regulated and 54 proteins significantly down-regulated (≥ twofold & P < .05) from EIF4G1 stably knockdown H1299 cell line when compared to the parental cell line. The top 10 significantly up-regulated or down-regulated proteins were listed in Table 1. Most of these downstream proteins have never been reported to be regulated by EIF4G1, whereas they showed a close protein-protein interaction network and potential functional association (Figure 4A). Interestingly, the Gene Ontology (GO) enrichment analysis indicated that many of EIF4G1-controlled proteins were involved in immune cell migration, chemotaxis, regulation of inflammatory responses, including cytokines and chemokines activities (Figure 4B-C). KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis indicated that the NF-κB signalling pathway activity was potentially affected by EIF4G1 (Figure S2A). The immunoblot results confirmed that knockdown of EIF4G1 by RNAi significantly reduced the phosphorylation of NF-κB p65 kinase from all the 3 NSCLC cell lines being tested (Fig. S2B). Notably, some recent studies have reported the regulation of immune checkpoint molecules by NF-κB signalling pathway in different types of cancer.22-24 Taken together, these data indicate again the potential immunoregulatory function of EIF4G1 network in NSCLC tumour cells.

3.5 | Novel EIF4G1-controlled cellular proteins, MUC1 and NRG1, functional validation and clinical implications in NSCLC

To further confirm protein array results with functional validation, two of EIF4G1-controlled proteins newly identified, MUC1 (Mucin 1) and NRG1 (Neuregulin 1), were selected for subsequent investigation. MUC1 is a transmembrane glycoprotein that is aberrantly overexpressed in > 80% of NSCLC.25 Moreover, the overexpression of MUC1 in NSCLC is associated with a poor disease-free and overall survival.26,27 Another EIF4G1-controlled protein, NRG1, is a ligand for the HER3 and HER4 receptors. NRG1 autocrine signalling has been implicated in insensitivity of NSCLC to EGFR inhibitors.28 Inhibition of NRG1- and other ligand-mediated HER4 signalling can consistently and significantly enhance the response to chemotherap-
FIGURE 2  Correlation of EIF4G1 and common immune checkpoint molecules in NSCLC biopsies. (A-B) RNA-Seq data sets of 20 LUAD (A) and 20 LUSC (B) samples were obtained from TCGA cohort. Gene expression was determined by the RSEM pipeline using GRCH38 reference genome as previously described. The Pearson correlations were calculated based on the gene TPM values and visualized as the heat maps using R packages. (C-D) IHC images of PD-1 (C) and PD-L1 (D) labelling from representative cases of NSCLC tissue arrays. (E-F) The box plots show expressional differences among these groups, including normal lung tissues (n = 10), tumour and paired adjacent tissues (n = 45 containing 19 cases of LUAD and 26 cases of LUSC). ** = P < .01; *** = P < .001; **** = P < .0001; NS: no significant
or normal lung tissues (Figure 6A-D). The Pearson correlations analysis indicated that EIF4G1 was positively correlated with NRG1 ($r = 0.35; P = .01$) rather than with MUC1 ($r = 0.23; P = .12$); interestingly, MUC1 and NRG1 displayed the strongest correlation in NSCLC ($r = 0.43; P = .003$). However, a higher number of NSCLC cases are needed for such analysis in future studies.

## DISCUSSION

Our previous study reported that EIF4G1 was significantly up-regulated in NSCLC cell lines compared to normal lung cells, which makes these lung cancer cells more susceptible to EIF4G1-targeted therapy. In the current study, we further demonstrate that EIF4G1 has much higher expression levels in NSCLC tumour tissues than paired adjacent or normal lung tissues by using tissue microarrays, regardless of EIF4G1 IHC labelling scores for each case. The solid evidence has been provided that EIF4G1 inhibitors (e.g., 4EGI-1 and 4E1RCat) display effective inhibition of NSCLC cell lines growth and tumorigenesis in vitro and in vivo. In contrast, these compounds show much less inhibitory effects on normal lung cells in the same doses range, because of the significant elevation of EIF4G1 and related protein levels in tumour cells. However, there are currently limited EIF4G1 specific inhibitors available. In a recent study, high-throughput drug screening identified SBI-0640756 as a new first-in-class inhibitor that targets EIF4G1 through disrupting the EIF4F complex and attenuates the growth of clinically unresponsive melanomas. Another recent study reported the design, synthesis, and in vitro characterization of a series of rigidified mimetic of 4EGI-1 in which the phenyl in the 2-(4-(3,4-dichlorophenyl)thiazol-2-yl) moiety was bridged into a tricyclic system. They found some analogues in this series to be markedly more potent than the parent prototypic inhibitor in the disruption of EIF4E/EIF4G interaction, and inhibition of human cancer cell proliferation. Therefore, the efficacy of these new compounds will be tested and compared for NSCLC once they are commercially available.

As mentioned before, recent immunotherapy studies have shown promising results on some NSCLC patients, despite of many existing challenges. One of key questions is how to improve immunotherapy efficacy through combination with other therapies including targeted therapy. In fact, EIF4E has been looked on as a node for regulation of immune functions via different translational control pathways, whereas much less known about EIF4G1 in this part. Here, we found that EIF4G1 has close associations with some immune checkpoint molecules such as PD-1 and PD-L1 in NSCLC by using RNA-Sequencing and tissue arrays data from cancer patients.
However, a lower positive labelling for PD-1 than PD-L1 was noticed in NSCLC tissues (Supplemental Table 1). Interestingly, one recent study reports that immunoreactivity loss driven by humidity and temperature results in structural distortion of epitopes rendering them unsuitable for antibody binding following epitope retrieval, especially during PD-L1 immunohistochemistry in FFPE tissues. It remains unclear whether PD-1 staining may have similar problems. To seek treatment benefits, we will explore whether EIF4G1 targeted therapy may improve immunotherapy (eg Pembrolizumab) in a new humanized NSCLC-PDX (Patient-derived xenograft) mice model recently established from the Jackson Laboratory.

Although the EIF4F complex may control cellular protein translation, the protein array analyses indicated that only a limited number of proteins were significantly changed within EIF4G1 stably knockdown H1299 cell line when compared to the controls, which is partially because of the detectable capability of protein array (~500 targets), even though these data imply the existence of a unique protein signature controlled by EIF4G1 in NSCLC cells. To prove that, we are currently working on getting other EIF4G1 stably knockdown NSCLC cell lines and normal lung cell lines by shRNA for protein array analyses. CRISPR (clustered regularly interspaced short palindromic repeats)/ Cas9 (CRISPR-associated gene 9) system is another option for gene editing, although completely knockout of EIF4G1 is probably difficult to be achieved because of its essential function. In this study, two significantly down-regulated proteins, MUC1 and NRG1, were selected from the candidate list of protein array results for functional validation. These data first confirmed that silencing of EIF4G1 by RNAi dramatically reduced the expression of both proteins in multiple NSCLC cell lines, which reflects the accuracy of protein array data and the cell line relevance. We actually also observed that knockdown of EIF4G1 partially reduced mRNA levels of MUC1 and NRG1 (data not shown), although the underlying mechanisms still require investigation (including additional factors probably involved in this regulation). Directly silencing of either MUC1 or NRG1 by siRNA significantly inhibited NSCLC cell growth and tumour formation in vitro and in vivo, implying that they can be used as potential therapeutic targets for NSCLC. Interestingly, one recent study reveals that MUC1 can activate PD-L1 expression in NSCLC cells for repression of immune effectors during cancer development. Another recent study also reports that evodiamine suppresses NSCLC by elevating CD8 + T cells and down-regulating the MUC1/PD-L1 axis. In addition, Pan et al recently have developed...
FIGURE 5  Direct targeting EIF4G1-controlled proteins inhibits NSCLC cell growth in vitro and in vivo. A-C, NSCLC cell lines (H460, A549, H1299) or normal human bronchial epithelial cells (NHBEC) were transfected with EIF4G1-siRNA, NRG1-siRNA, MUC1-siRNA or non-target control siRNA (n-siRNA) for 72 hours; then, protein expression was measured by immunoblots. Representative blots from one of two independent experiments were shown. D, The cells were transfected as above; then, cell proliferation was examined using the WST-1 assays (Roche). Error bars represent the SD for 3 independent experiments. ** = P < .01. (E-F) The H460 stably MUC1-shRNA, NRG1-shRNA knockdown cell lines (each with lentiviral vectors containing 2 shRNA specifically targeting: MUC1- or NRG1-KD1 and KD2, respectively) or control shRNA cell line were injected subcutaneously into nude mice. After 4 weeks, the mice were killed and tumours were excised and compared. Error bars represent SD for different mice in the same group. *** = P < .001
an anti-MUC1 antibody-drug conjugate synthesized by conjugating GSTA neoantigen-specific 16A with monomethyl auristatin E (MMAE), which displaying potent antitumoural efficacy towards various cancer cells including NSCLC. A strong correlation between MUC1 and NRG1 expression was also found in NSCLC based on our tissue array data, although the underlying mechanisms of their interaction or their contributions to EIF4G1-mediated cellular functions still require further investigation.

ACKNOWLEDGEMENTS
This work is supported by the Arkansas Bioscience Institute, the major research component of the Arkansas Tobacco Settlement Proceeds Act of 2000 and the Seeds of Science Pilot Award of Winthrop P. Rockefeller Cancer Institute (to ZQ). This work is also supported by a NIH COBRE grant (P20 GM121288), including the LCRC Molecular Histopathology and Analytical Microscope Core, a Tulane school of medicine faculty research pilot grant, and a Carol Lavin Bernick faculty grant (to ZL). HYL is also supported by the same NIH COBRE grant above. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

CONFLICT OF INTEREST
All the authors declare no conflicts of interest.

FIGURE 6 Elevation of MUC1 and NRG1 expression and their correlation with EIF4G1 in NSCLC tumour tissues. A-B, Immunohistochemical images of MUC1 (A) and NRG1 (B) from representative cases of NSCLC tissue arrays. (C-D) The box plots show expressional difference among these groups, including normal lung tissues (n = 10), tumour and paired adjacent tissues (n = 45 containing 19 cases of LUAD and 26 cases of LUSC). **** = P < .0001; NS: no significant

AUTHOR CONTRIBUTION
Luis Del Valle: Conceptualization (equal); Formal analysis (equal); Investigation (equal). Lu Dai: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Investigation (equal). Hui-Yi Lin: Formal analysis (equal). Zhen Lin: Methodology (equal). Jungang Chen: Investigation (equal). Steven Post: Conceptualization (equal). Zhiqiang Qin: Conceptualization (equal); Formal analysis (equal).

DATA AVAILABILITY STATEMENT
The data sets used and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Luis Del Valle https://orcid.org/0000-0003-3894-9206
Zhiqiang Qin https://orcid.org/0000-0002-9905-1275

REFERENCES
1. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 2017.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-594.
4. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
5. Wang C, Kulkarni P, Salgia R. Combined checkpoint inhibition and chemotherapy: new era of 1(st)-line treatment for non-small-cell lung cancer. Mol Thera Oncolytics. 2019;13:1-6.

6. Gainor JF, Shaw AT, Sequist LV, et al. EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016;22:4585-4593.

7. Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR Interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. 2019;25:989-999.

8. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14:261-278.

9. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 2010;115:2127-2135.

10. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N, elf4E-elf4GI from translation to transformation. Oncogene. 2004;23:3172-3179.

11. Prevot D, Darlix JL, Ohlmann T. Conducting the initiation of protein synthesis: the role of elf4E. Bioch. 2003;95:141-156.

12. Thumma SC, Jacobson BA, Patel MR, et al. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Ther. 2015;22:396-401.

13. Attar-Schneider O, Drucker L, Gottfried M. Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors elf4E and elf4GI. Lab Invest. 2016;96:1004-1015.

14. Li Y, Fan S, Koo J, et al. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13:272-280.

15. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The elf4E/elf4GI interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia. 2010;12:346-355.

16. Cao Y, Wei M, Li B, et al. Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. Oncotarget. 2016;7:24242-24251.

17. Dai L, Lin Z, Cao Y, Chen Y, Xu Z, Qin Z. Targeting EIF4F complex in non-small cell lung cancers. Oncotarget. 2017;8:55731-55735.

18. Dai L, Del Valle L, Miley W, et al. Transactivation of human endogenous retrovirus K (HERV-K) by KSHV promotes Kaposi's sarcoma development. Oncogene. 2018;37:4534-4545.

19. Chen J, Del Valle L, Lin HY, et al. Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation. Virology. 2019;536:16-19.

20. Li H, Li X, Liu S, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatol. 2017;66:1920-1933.

21. Dai L, Smith CD, Foroozesh M, Miele L, Qin Z. The sphinsesine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer. 2018;142:2153-2162.

22. Wang W, Chapman NM, Zhang B, et al. Upregulation of PD-L1 via HMGBl-Activated IRF3 and NF-kappaB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 2019;79:2909-2922.

23. Lucas J, Hsieh TC, Halicka HD, Darzynkiewicz Z, Wu JM. Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling. Int J Oncol. 2018;53:1469-1480.

24. Asgarova A, Asgarov K, Godet Y, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncotarget. 2018;7:e1423170.

25. Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28(suppl 1):S596-604.

26. Khodarev NN, Pitroda SP, Beckett MA, et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009;69:2833-2837.

27. Huang X, Sun Q, Chen C, et al. MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis. Oncotarget. 2017;8:90315-90326.

28. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10:39-50.

29. Hegde GV, de la Cruz CC, Chiu C, et al. Blocking NRG1 and other ligand-mediated Her receptor signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med. 2013;5:171ra118.

30. Feng Y, Pinkerton AB, Hulea L, et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the elf4F Translation Initiation Complex. Cancer Res. 2015;75:5211-5218.

31. Mahalingam P, Takrouni K, Chen T, et al. Synthesis of rigidified elf4E/elf4GI inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction. J Med Chem. 2014;57:5094-5111.

32. Piccirillo CA, Bjur E, Topisirovic I, Sonenberg N, Larsson O. Translational control of immune responses: from transcripts to translatomes. Nat Immunol. 2014;15:503-511.

33. Haragan A, Liebler DC, Das DM, et al. Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry. Lab Invest. 2020;100:874-886.

34. Wang M, Yao LC, Cheng M, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018;32:1537-1549.

35. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821.

36. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281-2308.

37. Bouillez A, Adeebee D, Jin C, et al. MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology. 2017;6:e1338998.

38. Jiang ZB, Huang JM, Xie YJ, et al. Evodiamine suppresses non-small cell lung cancer by elevating CD8(+) T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res. 2020;39:249.

39. Pan D, Tang Y, Tong J, et al. An antibody-drug conjugate targeting a GSTa glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. Cancer Med. 2020;9:9529-9540.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Del Valle L, Dai L, Lin H-Y, et al. Role of EIF4G1 network in non-small cell lung cancers (NSCLC) cell survival and disease progression. J Cell Mol Med. 2021;25:2795–2805. https://doi.org/10.1111/jcmm.16307